Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Germline BRCA-mutated HER2-negative Breast Cancer”

14 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 14 results

Testing effectiveness (Phase 2)Looking for participantsNCT04090567
What this trial is testing

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Who this might be right for
Advanced Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8+12 more
M.D. Anderson Cancer Center 60
Testing effectiveness (Phase 2)UnknownNCT02681562
What this trial is testing

Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Istituti Ospitalieri di Cremona 45
Testing effectiveness (Phase 2)Study completedNCT02789332
What this trial is testing

Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency

Who this might be right for
Breast CancerTriple Negative Breast NeoplasmsHRpos Breast Neoplasms+1 more
GBG Forschungs GmbH 107
Not applicableUnknownNCT04368442
What this trial is testing

Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation

Who this might be right for
Breast Cancer Metastatic
Samsung Medical Center 583
Testing effectiveness (Phase 2)Active Not RecruitingNCT04053322
What this trial is testing

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

Who this might be right for
ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancera Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
UNICANCER 172
Testing effectiveness (Phase 2)Active Not RecruitingNCT04584255
What this trial is testing

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Who this might be right for
Stage I Breast CancerStage II Breast CancerStage III Breast Cancer+5 more
Dana-Farber Cancer Institute 66
Large-scale testing (Phase 3)Ended earlyNCT01905592
What this trial is testing

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

Who this might be right for
Neoplasms, BreastCarcinoma of BreastHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast+3 more
Tesaro, Inc. 216
Testing effectiveness (Phase 2)Looking for participantsNCT05576389
What this trial is testing

Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study

Who this might be right for
Germline BRCA-mutated HER2-negative Breast Cancer
Peking University People's Hospital 64
Large-scale testing (Phase 3)UnknownNCT04296370
What this trial is testing

Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Who this might be right for
Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Jiangsu HengRui Medicine Co., Ltd. 474
Testing effectiveness (Phase 2)Ended earlyNCT03499353
What this trial is testing

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Who this might be right for
Early Breast Cancer
Pfizer 61
Not applicableLooking for participantsNCT05378204
What this trial is testing

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Institut Claudius Regaud 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT03330847
What this trial is testing

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Who this might be right for
Metastatic Triple Negative Breast Cancer
AstraZeneca 273
Large-scale testing (Phase 3)Active Not RecruitingNCT02032823
What this trial is testing

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 1,837
Not applicableEnded earlyNCT04436120
What this trial is testing

Treatment Resistance Following Anti-cancer Therapies

Who this might be right for
Disease Progression
Pfizer 38